CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2017 Chemotherapy Foundation Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer
Dr. Bendell on the Future of Regorafenib for Patients With CRC
Comparing Abiraterone and Docetaxel in Prostate Cancer Treatment
Oncology Conference Articles
Expert Discusses Treatment Options in Advanced CRC
Cathy Eng, MD, discusses optimizing sequencing beyond disease progression in CRC.
EGFR-Positive NSCLC Is Emerging as Model for Precision Medicine
It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with
-mutation–positive disease, says Edward S. Kim, MD.
Treating Advanced Non-Driver Lung Adenocarcinoma
The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.
MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology
Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.
PARPs Bring Excitement to Ovarian Treatment
PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.
How Reliable Is PD-L1 Expression as a Predictor of Immune Response?
There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.
Endometrial Cancer Enters Immunotherapy Age
The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.
Refining Role of Brentuximab Vedotin and Immunotherapy in Hodgkin Lymphoma
As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.
Profiling CLL Patients Likely to Progress on Available Agents
The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.
Better Outcomes in High-Risk Multiple Myeloma
Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.